Metamizoli Fonoviii. Parma (Metamizole Sodium)

Metamizole sodium works by inhibiting cyclooxygenase enzymes, reducing prostaglandin production, and thereby decreasing inflammation and pain signals. It also acts on central nervous system pathways to provide analgesia and influences the hypothalamus to lower body temperature.

The specific dose of Metamizoli Fonoviii. Parma is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Healthcare professionals should follow local guidelines and adjust the regimen as needed.

Safety data for metamizole sodium in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metamizole sodium is a non‑opioid analgesic that offers strong pain relief and antipyretic effects, often considered when NSAIDs are insufficient or contraindicated. Unlike opioids, it does not cause respiratory depression, but it carries a risk of rare blood disorders such as agranulocytosis.

Store the product at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight, and sources of heat to maintain stability and potency.

Metamizoli Fonoviii. Parma is supplied as a rectal formulation. It is inserted into the rectum according to the prescriber’s instructions, ensuring proper positioning for optimal absorption.

The most serious adverse reactions include agranulocytosis, severe skin reactions such as Stevens‑Johnson syndrome, and anaphylaxis. Patients should be monitored for signs of infection, rash, or breathing difficulties, and treatment should be stopped immediately if these occur.

Metamizoli Fonoviii. Parma should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, patients with a history of agranulocytosis, and in young children where safety has not been established. Clinicians should also exercise caution in patients with severe liver or kidney impairment.